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Abstract
Introduction: One of the rare ovarian neoplasms is sclerosing stromal tumor (SST). The most common age at presentation of scle-
rosing stromal tumor is the second and third decades of life. Usually this tumor presents with menstrual irregularity and pelvic
pain as reported previously. Surgery is mandatory for diagnosis because there is not any distinctive feature to diagnose by imaging
techniques.
Case Presentation: Our case in this report is a 26-year-old woman presented with pelvic pain. We conducted routine laboratory
tests and checked ovarian mass tumor markers preoperatively. Due to her normal hormonal status in physical examination, we did
not request more hormonal laboratory tests. However on imaging, we did not suspect benign tumor. Doppler sonography showed
low resistance flow in peripheral and center of the mass. Right ovarian mass was resected and diagnosed as ovarian stromal tumor
compatible with sclerosing stromal tumor. Unexpectedly at operation, we encountered severe hemorrhage from peritoneal surface
so that conservative management such as packing and suturing or cauterization was not helpful. Finally, argon coagulation stopped
bleeding. All coagulation laboratory tests requested by a hematologist were normal.
Conclusions: In conclusion, we believe that vascular endothelial growth factor (VEGF) production of tumor is responsible for mas-
sive bleeding.
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1. Introduction
Sclerosing stromal tumor (SST) is a rare ovarian neo-
plasm first described by Chavardjian and Scully in 1973.
This tumor occurs predominantly in young women (1).
Germ cell tumors occur at childhood and adolescence,
and other ovarian stromal tumors and epithelial neoplasm
normally happen in the 5th - 6th decade of life but scle-
rosing stromal tumor (SST) usually presents in the 2nd -
3rd decade of life (in younger women) (2). While in some
cases palpable tumor or virilization is detected, most of
the patients refer with menstrual irregularity (3). There
is no particular differentiation between SST and other ma-
lignant ovarian neoplasms on ultrasonography. The most
common presentation is mixed pattern including cystic
and solid components. However, due to predominant vas-
cular parts of SST, color Doppler ultrasonography of SST re-
veals prominent vascularity in the peripheral portion and
central intercystic spaces (4). It is difficult to definitely di-
agnose SST, preoperatively because it often mimics a malig-
nant tumor. Oophorectomy is usually performed in many
cases of young women, and diagnosis of SST is made based
on post-operative pathological examination (5). A previ-
ous study reported that vascular endothelial growth fac-
tors (VEGFs) are responsible for the vascular and edema-
tous changes of these tumors (3). In another study, twelve
cases of SST were analyzed immunohistochemically and
demonstrated the expression of vascular permeability fac-
tor/ VEGF(VPF/VEGF) in the luteinized theca-like cells and
the receptor in capillaries and even in medium sized blood
vessels. Accordingly, the characteristic vasculature and
edema of SSTs were considered to be associated with the ex-
pression of VPF/VEGF. In addition, three copies of chromo-
some 12 in 13% - 21% of all examined SST tumor cells were
reported using fluorescence in situ hybridization (FISH)
analysis (6).
2. Case Presentation
A 26-year-old woman was admitted to the oncology gy-
necology ward of Imam Khomeini hospital affiliated to
Tehran University of Medical Sciences, and presented with
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pelvic pain and menstrual irregularity for 4 months. On
recto abdominal digital examination, a large pelvic mass
was palpable. Vaginal examination was not carried out
because she was virgin. Her hormonal status was nor-
mal. Ultrasonography showed a large solid cystic mass
measured approximately 15 × 20 cm. Doppler sonogra-
phy showed low resistance in peripheral and central por-
tion of the mass. MRI showed multiseptated and thick
wall cystic mass in the central location of pelvic cavity. Tu-
mor markers including Alpha feto protein, lactate de hy-
drogenise, carsinoemberyonic antigen, beta human chori-
onic gonadotropin, and cancer antigen 125 levels were nor-
mal and due to normal hormonal status we did not request
more serological tests. Based on radiologic opinion, de-
spite normal tumor markers, we strongly suspected malig-
nancy. First, the patient was admitted with the diagnosis
of a malignant ovarian neoplasm. There was no significant
history in her family. Routine coagulation tests were nor-
mal. There was no free fluid in abdominopelvic cavity and
there was a large and float mass at right ovary. All parts of
the tissue seemed to be tumoral. Thus, right ovarian mass
was resected. The frozen section examination showed sex
cord-stromal tumor of ovary. Unexpectedly, we noticed
massive hemorrhage from pelvic peritoneal surface which
could not be stopped with routine methods such as pack-
ing and electrosurgery. 4 units packed cells and 4 units
fresh frozen plasma (FFP) were transfused intraoperatively.
Finally, we stopped it by argon coagulator. She discharged
after three days without more complications. The gross ex-
amination showed that the resected specimen consisted of
creamy grayish sheet-like tissue measuring 30×13 cm with
hemorrhage in some areas. The outer surface was smooth
and intact. Microscopic examination showed ovarian tis-
sue, lobular growth pattern of cellular and hypo cellular
areas composed of dual cell population. Collagen produc-
ing spindle cells and lipid-containing round to oval cells
were also seen. Interlobular fibrosis and marked vascular-
ity were identified. Finally, based on the pathologic perma-
nent report, sclerosing stromal tumor of ovary was diag-
nosed. After that, follow-up with physical examination and
sonography every three months was recommended to her.
Now, at the 9th month of follow-up, she is asymptomatic.
3. Discussion
Sclerosing stromal tumor is a rare ovarian neoplasm
first described by Chalvardjian et al. in 1973 (1) Ovarian stro-
mal tumors present in the 5th-6th decade of life but the
sclerosing type usually presents in the 2nd-3rd decade of
life; so, compared to other histological types, SST presents
at younger ages even in pregnancy (2). While in some cases
palpable tumor or virilization is detected, most patients
refer with menstrual irregularity (3). Color Doppler ultra-
sonography of SST reveals prominent vascularity in the pe-
ripheral portion and central intercystic spaces. Angiogen-
esis is a particularity of this type of neoplasm (4). Ultra-
sound finding indicates that they are of ovarian stromal
origin (7). Preoperative diagnosis is not helpful and it is
difficult to definitely diagnose because it often mimics a
malignant tumor. Oophorectomy is usually performed in
many cases of young women, and diagnosis of SST is made
based on post-operative pathological examination (5). As
mentioned before, growth factors (VPF/VEGF) can be re-
sponsible for the vascular and edematous changes of these
tumors (3). In a study, twelve cases of SST were analyzed im-
munohistochemically and demonstrated the expression
of VPF/VEGF (6). SST is an uncommon type of benign ovar-
ian sex cord-stromal tumor. As mentioned above, accord-
ing to younger age of women at presentation, clinical
symptoms of SST include premature menarche, menstrual
irregularities, abdominal discomfort and rarely, ascites (8).
The significance of these tumors is that it is necessary to
distinguish the histopathology in frozen sections in order
to protect the other adnexa, because of the characteristics
which are observed at early ages. Our findings support
that SSTs are benign tumors which stem from stroma and
they are hormonally active tumors based on per clinical
and immunohistochemistry (IHC) results, although there
are not any specific hormonal test that can support labora-
tory tests such as testosterone, estradiol, inhibin, etc. (9).
The characteristic histological finding of ovarian SST is the
pseudo lobular pattern that is formed by the cellular nod-
ules which are separated from each other by hypo cellu-
lar edematous and collagenous stroma. The hemangioper-
icytomatous pattern-like, dilated vascular structures are
the characteristics of cellular areas, and the luteinized
theca-like cells with vacuolated cytoplasm and fusiform
fibroblast-like cells are the characteristics of hyper cellular
areas. The characteristic pathological findings of the SST of
ovary were observed both macroscopically and microscop-
ically in all reported cases (10). For exact diagnosis after pre
operation preparation, ultrasound imaging, and routine
serologic tests, we performed laparotomy. Macroscopic ev-
idence did not show a benign mass strongly and the ovary
was tumoral universally; so oophorectomy was performed.
Frozen examination reported sex cord-stromal tumor, but
unexpectedly at operation, we encountered severe hemor-
rhage from peritoneal surface that conservative manage-
ment such as packing and suturing or cauterization was
not helpful. Finally, argon coagulation stopped bleeding.
All coagulation laboratory tests requested by a hematol-
ogist were normal postoperatively. In conclusion, we be-
lieve that VEGF production of tumor was responsible for
massive bleeding. As mentioned above, the expression of
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VPF/VEGF was detected in SST by IHC examination; there-
fore, our concept can support that the expression of VEGF
on the peritoneum surface is responsible for ongoing hem-
orrhage. We consulted a hematologist and requested com-
plete coagulation profile but our findings did not show any
abnormality. Now after 9 months, she does not present
symptoms and her clinical examination has no significant
findings and no lesion was observed on imaging study of
ovaries and pelvic.
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